Adagene (ADAG) Notes Payables (2019 - 2026)
Adagene (ADAG) posted quarterly Notes Payables of $4268.2 billion for Q4 2025, down 12.34% year-over-year from $4869.0 billion in Q4 2024, and up 203693259.97% quarter-over-quarter from $2.1 million in Q2 2025.
Analysis
Adagene (ADAG) Notes Payables (2019 - 2026) Analysis & Trends
Adagene (ADAG) has reported Notes Payables for 7 consecutive years, with $4268.2 billion the latest figure, recorded in Q4 2025.
- In Q4 2025, Notes Payables fell 12.34% year-over-year to $4268.2 billion; the TTM figure through Dec 2025 stood at $4268.2 billion (down 12.34% YoY), while the FY2025 annual figure was $4268.2 billion, down 12.34% from the prior year.
- Notes Payables climbed to $4268.2 billion in Q4 2025 per ADAG's latest filing, from $2.1 million in the prior quarter.
- Across five years, Notes Payables topped out at $10768.7 billion in Q4 2022 and bottomed at $2.1 million in Q2 2025.
- Historically, Notes Payables has averaged $3909.7 billion across 5 years, with a median of $4251.9 billion in 2023.
- Annual changes were most pronounced in 2022 — Notes Payables surged 345016409.54% — and 2024, when it plunged 100.0%.
- Adagene's Notes Payables stood at $3.1 million in 2021, then soared by 345016409.54% to $10768.7 billion in 2022, then slumped by 60.67% to $4235.7 billion in 2023, then increased by 14.95% to $4869.0 billion in 2024, then declined by 12.34% to $4268.2 billion in 2025.
- Business Quant data shows ADAG's Notes Payables at $4268.2 billion in Q4 2025, $2.1 million in Q2 2025, and $4869.0 billion in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Adagene | 211.24 Mn | 211.24 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.40 Mn |
| Dec 31, 2025 | 4.27 Mn |
| Jun 30, 2025 | 2.10 Mn |
| Dec 31, 2024 | 4.87 Mn |
| Jun 30, 2024 | 4.21 Mn |
| Dec 31, 2023 | 4.24 Mn |
| Jun 30, 2023 | 9.00 Mn |
| Dec 31, 2022 | 10.77 Mn |
| Jun 30, 2022 | 5.96 Mn |
| Dec 31, 2021 | 3.12 Mn |
| Jun 30, 2021 | 3.85 Mn |
| Dec 31, 2020 | 3.83 Mn |
| Dec 31, 2019 | 716,723.00 |